Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
- 363 Downloads
HER2 over-expression and/or amplification are present in 9-38% of gastric or gastroesophageal junction (GEJ) cancers and are correlated to poor outcome. We conducted a multicentre phase II trial to evaluate trastuzumab in combination with cisplatin in patients with untreated HER2-positive advanced gastric or GEJ cancer.
Materials and methods
Chemo-naïve patients with measurable, non-resectable, advanced or metastatic gastric or GEJ adenocarcinoma, with HER2 over-expression and/or amplification (IHC 3+, or IHC 2+ and FISH+), age ≥18 years, ECOG ≤2, left ventricle ejection fraction ≥50% and adequate organ function were eligible. Treatment consisted of trastuzumab (8 mg/kg on cycle 1 day 1 as loading; 6 mg/kg in subsequent cycles) and cisplatin (75 mg/m2), both intravenously on day 1, every 21 days.
Twenty-two out of 228 patients (10%) were HER2-positive and were included in this phase II trial. The median age was 66 years and ECOG 0/1 was 41%/59%. The median number of cycles was 4 (range 1–41). The confirmed ORR was 32% and disease control was achieved in 64% of patients. Median time to progression was 5.1 months. Grade 3 adverse events included asthenia (27%), neutropenia (18%), anorexia (14%), diarrhoea (9%) and abdominal pain (9%). There were no grade 4 toxicities or treatment-related deaths. Higher baseline HER extracellular domain (ECD) levels were associated with better outcome in terms of response and survival.
Trastuzumab in combination with cisplatin is an active regimen and has a favourable toxicity profile in advanced HER2-positive gastric or gastroesophageal cancers.
KeywordsGastric cancer Gastroesophageal junction adenocarcinoma HER2 Phase II Trastuzumab
- 2.Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:2004–2213Google Scholar
- 6.Yano T, Ochiai A, Doi T et al (2004) Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 22:14S(Abstr 4053)Google Scholar
- 8.Kang YK, Bang YJ, Lordick F et al (2008) Incidence of gastric or gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium p. 75 (abstr 11)Google Scholar
- 19.Roth AD, Maibach R, Martinelli G et al (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Res (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301–306Google Scholar
- 23.Fornier MN, Seidman AD, Schwartz MK et al (2006) Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234–239CrossRefGoogle Scholar
- 24.Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
- 25.Nicholas G, Cripps C, Au H-P et al (2006) Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. ESMO abstr 1105Google Scholar
- 26.Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096Google Scholar